Publication details

Transplantace střevní mikrobioty - historie, současnost a budoucnost

Title in English Fecal microbiota transplantation - past, present, and future
Authors

STEBEL Roman VOJTILOVÁ Lenka HUSA Petr

Year of publication 2020
Type Article in Periodical
Magazine / Source Gastroenterologie a hepatologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.prolekare.cz/casopisy/ceska-slovenska-gastro/2020-1-7/transplantace-strevni-mikrobioty-historie-soucasnost-a-budoucnost-121350
Doi http://dx.doi.org/10.14735/amgh202054
Keywords Clostridioides difficile; dysbiosis; fecal microbiota transplantation; microbial drug resistance; intestinal microbiome; pseudomembranous colitis
Description Distortions in intestinal microbial ecosystems are important pathogenetic factors of numerous diseases. The role of alterations in intestinal microbiota in the pathogenesis of recurrent clostridium colitis is well known. A fecal transfer from a healthy donor can restore natural homeostasis in intestinal microbiota and thus disrupt a „vicious circle“ of chronic relapsing clostridium infection. In the future, it should be possible to perform peroral fecal microbiota transplantations using enterosolvent tablets or commercially produced fecal derivatives. This administration route minimises the risk of adverse complications, which are rarely observed when fecal suspensions are administered via a nasoenteral probe, endoscopy, or by rectal clysma. In the past few years, intestinal microbiota transplantation has been used for the treatment of other diseases, the pathogenesis of which is probably associated with intestinal dysbiosis. In this respect, the most discussed issues are idiopathic intestinal inflammations, irritable bowel syndrome, liver encephalopathy and recently, „civilisation diseases“ such as diabetes mellitus type 2, multiple sclerosis, Parkinson’s disease, and metabolic syndrome. The fecal bacteriotherapy effect is observed also during the eradication of multi-resistant bacterial strains that colonise patients’ intestines. At present, fecal bacteriotherapy for recurrent clostridium colitis, as a proved medical method, is an accepted and world-wide recommended therapy. As for other diseases, this method is still in the experimental stage. Conclusive results of randomised control trials are expected.